Skip to main content
Frederick Locke, MD, Oncology, Tampa, FL, H. Lee Moffitt Cancer Center and Research Institute

FrederickLundryLockeMD

Oncology • Tampa, FL

Hematologic Oncology

Senior Member and Chair Department of Blood and Marrow Transplant and Cellular Immunotherapy and Co-Leader, Immunology Program Moffitt Cancer Center

Request Appointment

Overview of Dr. Locke

Dr. Frederick Locke is an oncologist in Tampa, FL and is affiliated with H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from Wayne State University School of Medicine and has been in practice 15 years. He specializes in hematologic oncology and is experienced in hematopoietic stem cell transplantation, non-hodgkin's lymphoma, immunology, and chimeric antigen receptor (CAR) t-cell therapy.

Education & Training

  • University of Chicago
    University of ChicagoFellowship, Hematology and Medical Oncology, 2006 - 2010
  • Wayne State University School of Medicine
    Wayne State University School of MedicineResidency, Internal Medicine, 2002 - 2006
  • Wayne State University School of Medicine
    Wayne State University School of MedicineClass of 2002

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2010 - 2025
  • IL State Medical License
    IL State Medical License 2006 - 2011
  • MI State Medical License
    MI State Medical License 2002 - 2007

Awards, Honors, & Recognition

  • Miles for Moffitt Scientist Award Moffitt Foundation, 2015
  • Internal Research Grant Award Recipient American Cancer Society, 2012
  • Clinical Research Training Institute Participant American Society of Hematology, 2011
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma
    Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple Myeloma
    Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Characteristics and Outcomes of Patients Who Did Not Develop CRS after Axicabtagene Ciloleucel for Relapsed/Refractory Large B-Cell Lymphoma: Results from the US Lymph...
    Frederick L. Locke, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia _ Clinical Updates and Innovations 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Patient-Reported and Neurocognitive Outcomes in Patients Treated with Axicabtagene Ciloleucel 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Phase 3 Study Results Show Metabolic Tumor Volume Improves Prognosis Compared to SPD in Second-Line R/R LBCL
    Phase 3 Study Results Show Metabolic Tumor Volume Improves Prognosis Compared to SPD in Second-Line R/R LBCLDecember 11th, 2022
  • Time to CAR T-cell Therapy May Impact Outcomes for Patients with Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
    Time to CAR T-cell Therapy May Impact Outcomes for Patients with Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR AnalysisDecember 11th, 2022
  • Body of Evidence Grows from ZUMA-7 Study Supporting Initial Treatment with Kite’s Yescarta® CAR T-cell Therapy for Patients with Relapsed or Refractory Large B-cell Lymphoma
    Body of Evidence Grows from ZUMA-7 Study Supporting Initial Treatment with Kite’s Yescarta® CAR T-cell Therapy for Patients with Relapsed or Refractory Large B-cell LymphomaDecember 11th, 2022
  • Join now to see all

Professional Memberships

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    Anthem Blue Access PPO
    Anthem Blue Preferred HMO
    Anthem Blue Preferred Plus POS
    AvMed Health Open Access
    BCBS Blue Card PPO
    BCBS Florida BlueCare HMO
    BCBS Florida NetworkBlue
    BCBS Florida Preferred Patient Care PPO
    BCBS Illinois PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Cofinity PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    Multiplan PPO
    Network Health Plan HMO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
    WEA Trust Preferred Provider Plan - Trust Pref
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Frederick Locke, Dr. Frederick Locke, MD, Dr. F Locke, Dr. Frederick Lundry Locke